Mity kontra fakty

Czyli medycyna prewencyjna w świetle najnowszych badań

lek. Katarzyna Świątkowska

przypisy do „przewodnika po syropkach i lekach na przeziębienie”

Share on facebook
Share on google
Share on twitter
Share on linkedin

1) Johnston S L, Holgate S T. Epidemiology of respiratory tract infections. In: Myint S, Taylor‐Robinson D, eds. Viral other infections of the human respiratory tract. London: Chapman & Hall, 1996
2) Morice AH, McGarvey L, Pavord I, British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. Thorax. 2006 Sep; 61 Suppl 1():i1-2
3) Herman Avner Cohen, Josef Rozen, Haim Kristal, Yoseph Laks, Mati Berkovitch, Yosef Uziel, Eran Kozer, Avishalom Pomeranz, Haim Efrat, Effect of Honey on Nocturnal Cough and Sleep Quality: A Double-blind, Randomized, Placebo-Controlled Study, Pediatrics, August 2012
4) Oduwole O, Meremikwu MM, Oyo-Ita A, Udoh EE., Honey for acute cough in children. Cochrane Database Syst Rev. 2014 Dec 23;(12):CD007094.
5) Paul I, Beiler J, McMonagle A, Shaffer ML, Duda L, Berlin CM Jr., Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med. 2007 Dec;161(12):1140-6.
6) Warren , Cooper, Honey improves cough in children compared to no treatment. J Pediatr. 2008 May;152(5):739-40. doi: 10.1016/j.jpeds.2008.02.023.
7) I Axelsson , Honey, not dextromethorphan, was better than no treatment for nocturnal cough in children with upper respiratory infections. Evid Based Med. 2008
8) Marleen Hamoen, Berna DL Broekhuizen, Paul Little, Hasse Melbye, Medication use in European primary care patients with lower respiratory tract infection: an observational study, Br J Gen Pract. 2014 Feb; 64(619): e81–e91.
10) Rimsza ME, Newberry S. Unexpected infant deaths associated with use of cough and cold medications. Pediatrics. 2008 Aug;122(2):e318-22. doi: 10.1542/peds.2007-3813.
11) Infant deaths associated with cough and cold medications–two states, 2005. MMWR Morb Mortal Wkly Rep. 2007 Jan 12;56(1):1-4.Centers for Disease Control and Prevention (CDC).
12) Hendley, J.O., and J.M. Gwaltney, Jr. 1988. Mechanisms of transmission of rhinovirus infections. Epidemiologic Reviews. 10:243-258
13) Gwaltney, J.M.Jr., and F.G. Hayden. 1992. Response to psychological stress and susceptibility to the common cold. New Engl. J. Med. 326:644-645.
14) Gwaltney, J.M.Jr., and R.R. Ruckert. 1997. Rhinovirus. In Clinical Virology. D.D. Richman, R.J. Whitley, and F.G. Hayden, editors. Churhill Livingstone, New York. 1025-1047.
15) Winther B, McCue K, Ashe K, Rubino J, Hendley JO., Rhinovirus contamination of surfaces in homes of adults with natural colds: transfer of virus to fingertips during normal daily activities. J Med Virol. 2011 May;83(5):906-9. doi: 10.1002/jmv.22027.
16) Douglas, R.G.J., K.M. Lindgren, and R.B. Couch. 1968. Exposure to cold environment and rhinovirus common cold. Failure to demonstrate effect. New Engl. J. Med. 279:743.
17) C.N. Camargo, E. Carraro, C.F. Granato, and N. Bellei, Human rhinovirus infections in symptomatic and asymptomatic subjects Braz J Microbiol. 2012 Oct-Dec; 43(4): 1641–1645.
18) Asymptomatic rhinovirus infection outnumbers symptomatic infection 4 to 1 among university students, Andrea Granados, Emma Goodall, Marek Smieja, James Mahony, 2012 American Society for Microbiology General Meeting, McFlu2 COLD3 clinical trial
19) Arroll B. Common cold. BMJ Clin Evid. 2011; 2011: 1510.
20) Kerrianne N. Huynh, Brian G. Oliver, Sacha Stelzer, William D. Rawlinson2, Euan R. Tovey, A New Method for Sampling and Detection of Exhaled Respiratory Virus Aerosols, Clin Infect Dis. (2008) 46 (1): 93-95.
21) Ryan MA, Christian RS, Wohlrabe J., Am J Prev Med. 2001 Aug;21(2):79-83. Handwashing and respiratory illness among young adults in military training.
22) Ejemot RI, Ehiri JE, Meremikwu MM, Critchley JA. Hand washing for preventing diarrhoea. Cochrane Database Syst Rev. 2008;1:CD004265.
23) Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health. 2008;98(8):1372-81.
24) Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health. 2008;98(8):1372-81.
25) Rabie T and Curtis V. Handwashing and risk of respiratory infections: a quantitative systematic review.Trop Med Int Health. 2006 Mar;11(3):258-67.
26) Inflammatory changes during the ‚common cold’ are associated with platelet activation and increased reactivity of platelets to agonists, Blood Coagul Fibrinolysis. 2007 Dec;18(8):713-8.
27) De Sutter AL., vanDriel ML , Kumar AA , Lessar, O Skrt A Oral antihistamine-decongestant- analgesic combinations for the common cold. Cochrane Syst Rev 2012 Feb15;2:CD004976
28) Antihistamines for the common cold (review) A.I.M. De Sutter, M. Lemiengre, H. Campbell,. MackinnonThe Cochrane Library, Issue 3, 2003. Chichester, UK: John Wiley & Sons, Ltd.,
29) De Blasio F, Dicpinigaitis PV, De Danieli G, Lanata L, Zanasi A. Efficacy of leveodropropizine in pediatric cough. Pulmanary Pharmacology & Therapeutics 2012; 25: 337 – 342.
30) Marchioni C.F., Moretti M., Muratori M.: Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 1990;168:285-93.
31) Olivieri D., Del Donno M., Casalini A., et al.: Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration 1991;58:91-94.
32) Marchioni C.F., Polu J.M., Taytard A., et al.: Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Therap 1995;33:612-18.
33) Braga P., Dal Sasso M., Zuccotti T.: Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzeneimittelforschung 2000;50:739-46.
34) Braga P., Zuccotti T., Dal Sasso M.: Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy 2001;47:208-14.
35) Titti G., Lizzio A., Termini C., et al.: A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine). Int J Clin Pharmacol Therap 2000;38:402-7.
36) Balli F., Bergamini B., Calistru P., et al.: Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Therap 2007;45:16-22.
37) WHO Pharmaceuticals Newsletter Nr. 1, 2007
38) Joseph D. Tobias, Thomas P. Green, Charles J. Coté, SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE, COMMITTEE ON DRUGS Codeine: Time To Say “No” American Academy of Pediatrics Clinical Report
39) Eccles R, Loose I, Jawad M, Nyman L, Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection. Pain Med. 2003 Jun; 4(2)
40) Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings., Cochrane Database Syst Rev. 2014 Nov 24; (11):CD001831. Epub 2014 Nov 24.
41) Bem J.L., Peck R.: Dextromethorphan: an overview of safety issues. Drug Saf. 1992, Tom 7, 190-199
42) J Pharm Pharmacol. 2000 Sep;52(9):1137-42.
Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory tract infection.
43) Bryner J., Wang U., Hui J., et al.: Dextromethorphan abuse in adolescent. Arch Pediatr Adolesc Med 2006;160;1217-22.
44) A H Morice, L McGarvey, and I Pavord,, Recommendations for the management of cough in adults, Thorax. 2006 Sep; 61(Suppl 1): i1–i24.
45) Chalumeau M, Duijvestijn YCM , Acetylcysteine and carbocysteine to treat acute upper and lower respiratory tract infections in children without chronic broncho-pulmonary disease, Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003124.
46) Effects of drugs on mucus glycoproteins and water in bronchial secretion.Medici TC, Radielovic P. J Int Med Res. 1979; 7(5):434-42.
47) Taverner D, Latte J: Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001953. DOI: 10.1002/14651858.CD001953. pub3.
48) One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment. Hallen H. J Otorhinolaryngol Relat Spec. 1997;59:39-44.
49) Ischemic colitis associated with pseudoephedrine: four cases. Dowd J, Bailey D, Moussa K, Nair S, Doyle R, Culpepper-Morgan JA. Am J Gastroenterol. 1999;94:2430–2434
50) Acute ischaemic colitis associated with oral phenylephrine decongestant use. Ward PW, Shaneyfelt TM, Roan RM. BMJ Case Rep. 2014 Jun 3;2014. pii: bcr2013202518. doi: 10.1136/bcr-2013-202518.
51) Probable Ischemic Colitis Caused by Pseudoephedrine with Tramadol as a Possible Contributing Factor Amelia A Traino Ann Pharmacother December 2004 vol. 38 no. 12 2068-2070 doi: 10.1345/aph.1E011
52) Drug-Induced Hypertension Darrell Hulisz, RPh, PharmD, Melissa Lagzdins, US Pharmacist. 2008;33(9):HS11-HS20.
53) Water potentiates the pressor effect of ephedra alkaloids. Jordan J, Shannon JR, Diedrich A, Black B, Robertson D, Biaggioni I. Circulation. 2004 Apr 20;109(15):1823-5. Epub 2004 Apr 5.
54) Effect of Oral Pseudoephedrine on Blood Pressure and Heart Rate A Meta-analysis. Stephen M. Salerno; Jeffrey L. Jackson; Elizabeth P. Berbano, Arch Intern Med. 2005;165(15):1686-1694. doi:10.1001/archinte.165.15.1686
55) Timing and number of minor infections as risk factors for childhood arterial ischemic stroke Nancy K. Hills, Stephen Sidney, and Heather J. Fullerton September 2, 2014, 83:10 890-897;
56) Perttu J. Lindsberg and Armin J. Grau , Inflammation and Infections as Risk Factors for Ischemic Stroke , Stroke. 2003;34:2518-2532
57) Graham NM, Burrell CJ, Douglas RM, Debelle P, Davies L., Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. The Journal of infectious diseases, 1990
58) Stanley ED, Jackson GG, Panusarn C, Rubenis M, Dirda V. Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA 1975;231:1248-1251.
59) Korppi M., Kotaniemi-Syrjanen A., Waris M., et al.: Rhinovirus-associated wheezing in infancy: a comparison with respiratory syncytial virus bronchiolitis. Pediatr Infec Dis J 2004;23:995-9.
60) Foulongne V., Guyon G., Rodiere M., et al.: Human metapneumovirus infection in young children hospitalised with respiratory tract disease. Pediatr Infec Dis J 2006;25:354-9.
61) Curley F., Irwin R., Pratter M., et al.: Cough and common cold. Am Rev Respir Dis 1988;138:305-11.
62) O`Brien K., Dowell S., Schwartz B., et al.: Cough illness bronchitis. Pediatrics 1998;101(Suppl.):S178-181.
63) Snow V., Mattur C., Gonzales R.: Clinical practice guideline, part 1. Principles of appropriate antibiotic use for treatment ofacute bronchitis in adults. Ann Intern Med 2001;134:518-20.
64) 3. Gonzales R., Sande M.: Uncomplicated acute bronchitis. Ann Intern Med 2000;133:981-991.
65) Henk A., Postma D., Bock G., et al.: Asthma in adult patients presenting with symptoms of acute bronchitis in general practice. Scand J Prim Health Care 2000;18:188-92.
66) How long does a cough last? Comparing patients’ expectations with data from a systematic review of the literature., Ebell MH, Lundgren J, Youngpairoj S, Ann Fam Med. 2013 Jan-Feb; 11(1):5-13.
67) Thompson M i wsp. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013; 347: f7027.
68) Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010 Feb;16(2):228-31. doi: 10.1038/nm.2087. Epub 2010 Jan 17
69) Hill DA, Siracusa MC, Abt MC, Kim BS, Kobuley D, Kubo M, Kambayashi T, Larosa DF, Renner ED, Orange JS, Bushman FD, Artis D, Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation.Nat Med. 2012 Mar 25; 18(4):538-46.
70) Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, Iwasaki A, Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A. 2011 Mar 29; 108(13):5354-9.
71) Fitzgerald K, NLR-containing inflammasomes: central mediators of host defense and inflammation. Eur J Immunol. 2010 Mar; 40(3):595-8.
72) Allen IC, et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 2009;30:556–565.
73) Thomas PG, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity. 2009;30:566–575.
74) Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009;16:79–87
75) Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. Kollar C, Schneider H, Waksman J, et al. Clin Ther 2007;29:1057-70.
76) Efficacy and safety of oral phenylephrine: systematic review and metaanalysis. Hatton RC, Winterstein AG, McKelvey RP, et al. Ann Pharmacother 2007;41:381-90.
77) Lars Marquardt , A common cold is no stroke of luck, Neurology September 2, 2014 vol. 83 no. 10 872-873
78) Intranasally and orally administered antihistamine treatment of experimental rhinivirus colds. Gaffey, Gwaltney, Sastre A, et al. Am Rev Respir Dis 1987; 136: 556-60.
79) Effectivness of antihistamines in the symptomatic management of the common cold. Howard JC Jr, Kantner TR, Lilienfield LS, et al. JAMA 1979; 242: 2414-17
80) The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis. D’Agostino RB Sr, Weintraub M, Russell HK, et al. Clin Pharmacol Ther 1998; 64: 579-96.
81) Antihistamines for the common cold. Sutter AI, Lemiengre M, Campbell H, et al. Cochrane Database Syst Rev 2003;(3): CD001267.
82) Kenealy T, Arroll Bin, Antibiotics for the common cold and acute purulent rhinitis.Cochrane database of systematic reviews, June 2013
83) Diehr P., Wodo R., Bushyhaed J., et al.: Prediction of pneumonia in outpatients with acute cough – a statistical approach. J Chronic Dis 1984;37:215-25.
84) Public Health Advisory. FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age. 2008.
85) Lee P.C.L., Jawad M.S., Eccles R.: Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory tract infection. J Pharm Pharmacol 2000;52:1137-42.
86) Tukiainen H., Karttunen P., Silvasti M., et al.: The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-2-sympathomimetic combination. Eur J Respir Dis 1986;69:95-9.
87) Taylor J.A., Novack A.H., Almquist J.R., Rogers J.E.: Efficacy of cough suppressants in children. J Pediatr 1993;122:799-802.



Zostaw komentarz

Twój adres email nie zostanie opublikowany.

Zostaw komentarz

Katarzyna Świątkowska

lekarz medycyny

Jestem absolwentką Akademii Medycznej w Gdańsku, mieszkam i prowadzę praktykę lekarską w pięknym mieście na Pomorzu Zachodnim.
Od lat staram się przekonywać swoich pacjentów i czytelników mojej strony, że dbałość o zdrowie nie polega na gonitwie za modnymi suplementami i magicznej wierze, że lekarz załatwi za nas wszystko.
Zależy mi niezwykle, by najnowsze doniesienia naukowe dotarły do jak najszerszego kręgu odbiorców. Przyznaję, że traktuję to jako moją misję życiową.